Maribavir Synthesis Using Form VI Crystallization to Cut Impurities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing syntheses of maribavir, an antiviral medication for cytomegalovirus (CMV) infection, suffer from low overall yields and impurities, which affect the quality and safety of the drug product.
Innovation Solution
An improved synthesis of maribavir is developed, involving specific reaction conditions and purification methods to enhance yield and minimize impurities, particularly through controlled crystallization and formulation of the polymorphic Form VI, ensuring a particular particle size distribution and reducing impurities to acceptable levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthesis methods are used, then the synthesis process can be completed, but the overall yield is low (27-49%) and impurities are generated
Solution Approach 1:
The patent changes reaction parameters including solvent selection (DMF, NMP, DMSO), temperature profiles, and stoichiometry to optimize each synthesis step. The crystallization step uses specific solvent combinations and temperature control to achieve high purity while maintaining yield above 45%
Solution Approach 2:
The patent employs extraction techniques during purification to remove impurities from the reaction mixture. Crystallization is used to separate the desired product from byproducts and starting materials, effectively extracting the pure compound from the complex reaction mixture
Solution Approach 3:
The patent performs preliminary protection of hydroxyl groups as acetonides before the main coupling reaction. This preliminary action prevents side reactions and simplifies the overall synthesis by pre-organizing the molecular structure for the subsequent nucleophilic substitution
2Ease of manufacture
If multiple synthesis steps are used, then the complete maribavir molecule can be formed, but the process complexity increases and yield decreases
Solution Approach 1:
The patent combines the nucleophilic substitution and crystallization steps into an integrated process where the reaction mixture is directly subjected to controlled crystallization. This merging eliminates intermediate filtration and transfer operations, reducing loss and simplifying the manufacturing process
Solution Approach 2:
The synthesis is divided into distinct modular steps: protection, coupling, and deprotection/crystallization. Each module can be independently optimized and scaled, making the overall process easier to manufacture while maintaining high yield through standardized operating procedures
3Object-generated harmful factors
If purification steps are added, then impurities are reduced, but the manufacturing time and complexity increase
Solution Approach 1:
The patent utilizes controlled crystallization as the primary purification method, leveraging phase transition from dissolved to solid state. This single step achieves both purification and concentration, eliminating the need for multiple sequential purification operations and reducing manufacturing time
Solution Approach 2:
The patent converts the byproducts and excess reagents from harmful impurities into beneficial crystallization seeds that promote pure product formation. The controlled crystallization process selectively incorporates the desired product while excluding impurities, turning the complex reaction mixture into a purification opportunity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved synthesis achieves yields of at least 45% and produces maribavir with reduced impurities, enhancing the drug's quality and safety for oral formulations.
Implementation Method 1
controlled crystallization and formulation of the polymorphic Form VI
Data Source
AI summary
The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir. Maribavir is a benzimidazole riboside and is useful as an antiviral.